Grupo Prodol grows in China through Cofides
Grupo Prodol crece en China con la ayuda de Cofides
Intel ID : 225825
| Synopsis |
|
Spain-based Grupo Prodol, a manufacturer of medical equipment, increase its activity in China through a co-investment loan from fund Fonpyme, controlled by Cofides, for EUR 0.35m, as disclosed by Cofides in a press release published on 2 June 2015. With this deal, manufacture and marketing of a new medical device with Spanish design in China will be encouraged. Growth prospects in China are high, with an estimated annual growth of 14% from 2013-2020. Grupo Prodol Meditec was created in Bilbao in 2003, and manufactures and sells Airtraq, a group of intubation products for surgical interventions. Currently more than 5,000 hospitals worldwide use Grupo Prodol's Airtraq device. Cofides is a public-private partnership providing financial support since 1988, for Spanish companies' investments abroad. It exclusively manages funds Fiex and Fonpyme.
(content in spanish)
La empresa española Grupo Prodol, dedicada a la fabricación de material médico, aumentará su actividad en China gracias a un préstamo de coinversión a cargo del fondo Fonpyme, perteneciente a Cofides, por un valor de EUR 0,35m, según ha informado Cofides en una nota de prensa el 2 de junio de 2015. Con esta operación se favorecerá la fabricación y comercialización de un nuevo producto sanitario con diseño español en China. Las perspectivas de crecimiento en China son altas, estimándose un crecimiento anual del 14% de 2013 a 2020. Grupo Prodol Meditec es una empresa creada en Bilbao en 2003 dedicada a la fabricación y comercialización de Airtraq, un grupo de productos destinados a intubación en intervenciones quirúrgicas. Actualmente más de 5.000 hospitales de todo el mundo utilizan el dispositivo Airtraq del Grupo Prodol. Cofides es una sociedad público-privada que desde 1988 ofrece apoyo financiero a las inversiones de las empresas españolas en el exterior. Gestiona en exclusiva los fondos Fiex y Fonpyme. |
| Intel ID | 225825 | ||
| Value | EUR 0,35m | ||
| Native Currency | Euro (EUR) | ||
| Date |
|
||
| Country | ![]() |
||
| Region | |||
| Continent | ![]() |
||
| Geography | ![]() |
||
| Subsector (Old TTR Sectors) |
|
||
| Type |
|
||
| Intel Grade |
|
||
| Source |
|
||
| Tags | ![]() |
Bidder
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Country |
|
||
| Description |
|
Related Entity
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
25.01.04 Consumer Finance 25 Financial Services / 25.01 Banking & Investment |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.